The Oligonucleotide Synthesis Market size was valued at USD 3.72 billion in 2023 and is projected to reach USD 11.41 billion by 2032, growing at a 13.27% CAGR over the forecast period of 2024-2032.
Get more information on Oligonucleotide Synthesis Market - Request Free Sample Report
This report points to the incidence and prevalence of target diseases, which fuel demand for oligonucleotide therapeutics in genetic disorders, infectious diseases, and oncology. R&D and drug development pipeline trends, including rising investment in RNA-based treatment modalities and gene-editing platforms, are fueling innovation, while synthesis technology trends, including advances in automation and high-throughput methods, are enhancing efficiency and scalability. The report discusses healthcare and biopharma investment trends with a focus on increasing financial backing for oligonucleotide-based drug development. Additionally, regulatory advancements and oligonucleotide-based drug approvals are reviewed, in line with the increased clinical utilization of these therapies.
The U.S. Oligonucleotide Synthesis Market was valued at USD 1.21 billion in 2023 and is expected to reach USD 3.38 billion by 2032, growing at a CAGR of 12.13% over the forecast period of 2024-2032. In the United States, the market is experiencing accelerated growth based on robust government support for genetic research, increasing alliances between pharmaceutical companies and biotech players, as well as a conducive regulatory environment encouraging speedy drug approvals.
Drivers
The growing demand for synthetic oligonucleotides in therapeutic and diagnostic applications is a key driver of the market.
As the incidence of genetic disorders, cancer, and infectious diseases is on the rise, oligonucleotide-based therapeutics like antisense oligonucleotides, siRNA, and CRISPR-based gene editing are on the rise. Various oligonucleotide-based drugs have been approved by the U.S. FDA, such as Nusinersen for spinal muscular atrophy and Inclisiran for cholesterol lowering, which is further driving market growth. Moreover, the development of automated synthesis technologies has enhanced the efficiency of production, making it cost-effective and more scalable. Growing usage of polymerase chain reaction (PCR) and next-generation sequencing (NGS) in clinical diagnostics has also spurred the use of oligonucleotides, particularly PCR primers and sequencing reagents. Growing investments in genomic research and drug discovery by biotech and pharma firms are also boosting oligonucleotide synthesis innovation. The combination of artificial intelligence (AI) and machine learning in oligonucleotide optimization and design is speeding up drug discovery while enhancing the effectiveness of custom synthesis services. Additionally, the increasing adoption of personalized medicine and precision therapeutics is poised to ensure long-term growth in this market. The growth of more partnerships between biotech companies and contract synthesis businesses is expanding the accessibility and geographic reach of the market further.
Restraints
The oligonucleotide synthesis market faces significant restraints, primarily associated with high costs and complex manufacturing processes.
Synthesis of high-purity oligonucleotides involves costly raw materials, specialized equipment, and rigorous quality control, contributing to higher costs of production. For instance, phosphoramidites, the key building blocks for oligonucleotide synthesis, are expensive and sensitive to storage conditions, affecting supply chain efficiency. Regulatory barriers also represent a significant limitation, with strict guidelines by regulatory bodies such as the FDA and EMA requiring stringent validation and compliance, prolonging product approvals. Moreover, concerns over the safety and efficacy of oligonucleotide-based therapeutics due to the possibility of off-target effects and toxicity hold back their broad-based clinical usage. Intellectual property (IP) concerns over synthesis technologies and proprietary sequences also hamper market entry for new entrants. The heavy upfront investment needed to establish synthesis facilities acts as a deterrent for small biotech companies to enter the market. In addition, the poor scalability of existing synthesis technologies, especially for large-scale production, limits the capacity of manufacturers to respond efficiently to increasing demand. Also, the absence of standardized synthesis protocols and batch-to-batch variability further inhibit the use of oligonucleotides in high-throughput applications.
Opportunities
The expanding applications in gene therapy, molecular diagnostics, and personalized medicine.
The success of COVID-19 vaccines, fueling the growth of mRNA therapeutics, has given way to novel opportunities for developing drugs based on oligonucleotides. Progress in CRISPR-Cas gene editing technology has propelled demand for synthetic guide RNAs further, again propelling the market. The heightened emphasis on rare diseases has created greater interest in oligonucleotide-based orphan drugs, and regulatory benefits are encouraging research here. The advent of affordable and automated oligonucleotide synthesis platforms has opened doors for biotech companies and startups to come into the market with new solutions. In addition, the increasing usage of next-generation sequencing (NGS) and liquid biopsy methods in oncology has supported the demand for oligonucleotides of high quality. The partnerships between academic research centers and pharmaceutical firms are speeding up the transition of oligonucleotide-based treatments from bench to bedside. The growth of contract development and manufacturing organizations (CDMOs) is enabling biotech firms to access cost-effective synthesis solutions, enabling speedy commercialization. The Asia-Pacific region, with emerging markets, presents untapped opportunities as there is growing investment in biotechnology infrastructure and enhanced awareness of genetic-based therapies.
Challenges
The oligonucleotide synthesis market faces several challenges, primarily related to scalability, stability, and regulatory compliance.
One of the biggest challenges is the inability to scale up manufacturing with high efficiency due to high purity. Oligonucleotide synthesis on a large scale requires careful reagent handling, optimized purification processes, and rigid quality control protocols, all of which add to the complexity of the operation. The stability of synthetic oligonucleotides is another big challenge since they are very susceptible to nucleases-mediated degradation, rendering transport and storage problematic. Ensuring the long-term stability of oligonucleotide therapeutics is an important issue in drug development. Regulatory issues also introduce challenges, with changing guidelines and safety issues slowing down clinical approvals. The risk of immunogenicity and off-target activities of therapeutic oligonucleotides is a challenge to be met by rigorous preclinical and clinical testing. Competition from other therapeutic strategies, including monoclonal antibodies and small-molecule drugs, is also restricting the use of oligonucleotide-based therapies. Regulatory issues related to gene-editing tools, especially those based on CRISPR technologies, add an extra layer of complexity to pathways. Lastly, the dependence of suppliers on limited players for significant raw materials, including phosphoramidites, leaves the supply chain susceptible to disruption, which impacts production times and costs. All these pose a challenge in addressing through further innovations in synthesis technologies and enhancing regulatory systems.
By Product & Service
The services segment led the oligonucleotide synthesis market in 2023 with a 37.4% share. This leadership is due to the growing outsourcing of oligonucleotide synthesis by pharmaceutical and biotechnology industries. The requirement for tailored oligonucleotide synthesis, modification, and purification services has risen with growing uses in drug discovery and molecular diagnostics. The difficulty and high cost of in-house synthesis have further driven the dependency on service providers.
The oligonucleotide segment is anticipated to witness the maximum growth in the coming years. The rising demand for therapeutic applications of synthetic oligonucleotides for antisense therapy, siRNA, and gene editing technologies propels this expansion. The augmented pipeline of drug candidates based on oligonucleotides, as well as augmenting research areas in genomics and molecular biology are the central drivers driving rapid growth in this segment.
By Application
The PCR primers segment dominated the largest market share in 2023 due to its extensive application across research, diagnostics, and clinical use. PCR primers are essential for polymerase chain reaction (PCR) assays, which are a standard technique in genetic testing, the detection of infectious diseases, and forensic analysis. Its growing application of PCR-based diagnostics, especially for infectious disease tests and oncology, has entrenched its position as the top-performing segment.
The sequencing segment is anticipated to see the highest growth in the forecast period. The growing need for next-generation sequencing (NGS) technologies, the development of precision medicine, and the decreasing cost of sequencing have greatly fueled this segment. The growing incorporation of sequencing-based methods in clinical diagnostics, oncology, and genetic disease research is fueling its high growth.
North America was the leading oligonucleotide synthesis market in 2023, with high investment in genomic research, robust presence of pharmaceutical and biotech firms, and growing utilization of oligonucleotide-based therapeutics. The U.S. is followed by the rest of the region because of sheer funding for gene therapy and precision medicine programs. FDA approval of oligonucleotide-based pharmaceuticals such as Nusinersen and Inclisiran has also increased market growth. Furthermore, growth in next-generation sequencing (NGS) and polymerase chain reaction (PCR) uses in diagnostics has complemented the demand for synthetic oligonucleotides in research and clinical applications.
Asia-Pacific is the fastest-growing market, set to grow at a high rate over the forecast period. Increased growth in the biotechnology industries of China, India, and Japan, increased government expenditure on genomics, and rising investments in personalized medicine are primary drivers. China, for instance, is experiencing an upsurge in oligonucleotide-based drug discovery and sequencing technology, supported by government programs such as the "China Precision Medicine Initiative". The rising incidence of infectious diseases and genetic diseases in Asia-Pacific has further fuelled demand for oligonucleotide synthesis. Furthermore, the availability of low-cost manufacturing centers and growing research partnerships between international pharmaceutical majors and Asian biotech organizations are fuelling regional market growth.
Get Customized Report as per Your Business Requirement - Enquiry Now
Thermo Fisher Scientific, Inc. – Custom Oligos, GeneArt Oligonucleotide Services, Invitrogen Oligos
Merck KGaA (MilliporeSigma) – Custom DNA & RNA Oligos, OligoPilot, Proligo Oligonucleotides
Danaher Corporation (Integrated DNA Technologies - IDT) – gBlocks Gene Fragments, Ultramer DNA & RNA Oligos, PrimeTime qPCR Probes
Dharmacon Inc. (Horizon Discovery, a PerkinElmer company) – Custom siRNA, CRISPR Guide RNAs, RNAi Oligos
Agilent Technologies – SureSelect Oligonucleotide Probes, Custom DNA/RNA Synthesis
Bio-Synthesis, Inc. – Custom Oligonucleotides, Peptide-Oligonucleotide Conjugates, siRNA Synthesis
Kaneka Eurogentec S.A. – Custom DNA & RNA Oligonucleotides, GMP-Grade Oligos, qPCR Probes
LGC Biosearch Technologies – Black Hole Quencher (BHQ) Probes, Stellaris RNA FISH Probes, Custom Oligonucleotides
Biolegio – Custom DNA & RNA Oligos, NGS Adapters, qPCR & FISH Probes
Twist Bioscience – Synthetic DNA Oligos, NGS Panels, CRISPR Oligos, Gene Synthesis Services
In December 2024, PeptiSystems raised 45 MSEK in funding, led by Sciety and Sciety Venture Partners, to scale up peptide and oligonucleotide drug manufacturing. The investment will enhance production capacity, sales expansion, and sustainable pharmaceutical manufacturing efforts.
In Nov 2024, Codexis, Inc. announced new data at the TIDES Europe 2024 conference, showcasing advancements in its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis platform. The findings highlight Codexis’s leadership in enzymatic synthesis technology, supporting the scalable manufacturing of RNAi therapeutics.
In July 2024, EnPlusOne Biosciences announced a breakthrough in enzymatic RNA synthesis by successfully synthesizing the antisense strand of Leqvio (inclisiran), a commercially approved siRNA drug for hypercholesteremia. Licensed by Novartis from Alnylam Pharmaceuticals, Leqvio currently serves a multi-million patient population.
| Report Attributes | Details |
| Market Size in 2023 | USD 3.72 billion |
| Market Size by 2032 | USD 11.41 billion |
| CAGR | CAGR of 13.27% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product & Service [Oligonucleotides, Equipment/Synthesizer, Reagents, Services] • By Application [PCR Primers, PCR Assays and Panels, Sequencing, DNA Microarrays, Fluorescence In Situ Hybridization (FISH), Antisense Oligonucleotides, Other Applications] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific, Merck KGaA, Danaher Corporation (IDT), Dharmacon Inc., Agilent Technologies, Bio-Synthesis Inc., Kaneka Eurogentec S.A., LGC Biosearch Technologies, Biolegio, and Twist Bioscience. |
Ans: The Oligonucleotide Synthesis Market size was valued at US$ 3.67 billion in 2023 and is expected to reach USD 11.41 billion in 2032.
Ans: The Oligonucleotide Synthesis Market is expected to grow at 13.27% CAGR from 2024 to 2032.
Ans: Oligonucleotide Synthesis Market size was valued at USD 3.72 billion in 2023.
Ans: Rising demand for Covid-19 diagnostics and increasing government initiatives.
Ans: Yes, you may request customization based on your company's needs.
Table of contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Targeted Diseases (2023)
5.2 R&D and Drug Development Pipeline Trends (2023- Present)
5.3 Synthesis Technology Trends (2023- Present)
5.4 Healthcare and Biopharma Investment Trends (2023)
5.5 Oligonucleotide-Based Drug Approvals (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Oligonucleotide Synthesis Market Segmentation, by Product & Service
7.1 Chapter Overview
7.2 Oligonucleotides
7.2.1 Oligonucleotides Market Trends Analysis (2020-2032)
7.2.2 Oligonucleotides Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Equipment/Synthesizer
7.3.1 Equipment/Synthesizer Market Trends Analysis (2020-2032)
7.3.2 Equipment/Synthesizer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Reagents
7.4.1 Reagents Market Trends Analysis (2020-2032)
7.4.2 Reagents Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Services
7.5.1 Services Market Trends Analysis (2020-2032)
7.5.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Oligonucleotide Synthesis Market Segmentation, by Application
8.1 Chapter Overview
8.2 PCR Primers
8.2.1 PCR Primers Market Trends Analysis (2020-2032)
8.2.2 PCR Primers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 PCR Assays and Panels
8.3.1 PCR Assays and Panels Market Trends Analysis (2020-2032)
8.3.2 PCR Assays and Panels Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Sequencing
8.4.1 Sequencing Market Trends Analysis (2020-2032)
8.4.2 Sequencing Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 DNA Microarrays
8.5.1 DNA Microarrays Market Trends Analysis (2020-2032)
8.5.2 DNA Microarrays Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Fluorescence In Situ Hybridization (FISH)
8.6.1 Fluorescence In Situ Hybridization (FISH) Market Trends Analysis (2020-2032)
8.6.2 Fluorescence In Situ Hybridization (FISH) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Antisense Oligonucleotides
8.7.1 Antisense Oligonucleotides Market Trends Analysis (2020-2032)
8.7.2 Antisense Oligonucleotides Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Other Applications
8.8.1 Other Applications Market Trends Analysis (2020-2032)
8.8.2 Other Applications Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.2.4 North America Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.2.5.2 USA Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.2.6.2 Canada Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.2.7.2 Mexico Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.5.2 Poland Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.6.2 Romania Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.4 Western Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.5.2 Germany Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.6.2 France Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.7.2 UK Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.8.2 Italy Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.9.2 Spain Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.12.2 Austria Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.4 Asia Pacific Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.5.2 China Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.5.2 India Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.5.2 Japan Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.6.2 South Korea Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.2.7.2 Vietnam Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.8.2 Singapore Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.9.2 Australia Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.4 Middle East Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.5.2 UAE Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.2.4 Africa Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Oligonucleotide Synthesis Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.6.4 Latin America Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.6.5.2 Brazil Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.6.6.2 Argentina Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.6.7.2 Colombia Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Oligonucleotide Synthesis Market Estimates and Forecasts, by Product & Service (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Oligonucleotide Synthesis Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10. Company Profiles
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 Merck KGaA (MilliporeSigma)
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Danaher Corporation (Integrated DNA Technologies - IDT)
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Dharmacon Inc. (Horizon Discovery, a PerkinElmer company)
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Agilent Technologies
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Bio-Synthesis, Inc.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Kaneka Eurogentec S.A.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 LGC Biosearch Technologies
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Biolegio
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Twist Bioscience
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product & Service
Oligonucleotides
Equipment/Synthesizer
Reagents
Services
By Application
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In Situ Hybridization (FISH)
Antisense Oligonucleotides
Other Applications
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Bispecific Antibodies Market size was valued at USD 8.28 billion in 2023 and is expected to reach USD 220.82 billion by 2032, at a CAGR of 44.05% by 2024-2032.
The Lateral Flow Assays Market Size was valued at USD 10.94 billion in 2023 and is expected to reach USD 18.59 billion by 2032 and grow at a CAGR of 6.09% over the forecast period 2024-2032.
The Immunology Market Size was valued at USD 97.58 Billion in 2023, and is expected to reach USD 254.23 Billion by 2032, and grow at a CAGR of 11.8%.
Plant-based Excipients Market Size was valued at USD 1.9 billion in 2023 and is expected to reach USD 2.5 billion by 2032, growing at a CAGR of 3.0% over the forecast period 2024-2032
The Robotic Nurse Assistant Market Size was USD 1.27 Billion in 2023 and will reach USD 4.55 Billion by 2032 and grow at a CAGR of 15.27% by 2024-2032
Sterilization Equipment Market Size was valued at USD 7.0 Billion in 2023 and is expected to reach USD 18.44 Billion by 2032, growing at a CAGR of 11.38% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
